Literature DB >> 29091742

Biosecurity Implications for the Synthesis of Horsepox, an Orthopoxvirus.

Diane DiEuliis1, Kavita Berger1, Gigi Gronvall1.   

Abstract

This article examines the biosecurity and biodefense implications resulting from the recent creation of horsepox virus, a noncirculating (extinct) species of orthopoxvirus. Here we examine the technical aspects of the horsepox virus synthesis and conclude that orthopox synthesis experiments currently remain technically challenging-and will continue to be so, even once this work is published in the scientific literature. This limits potential misuse by some types of nefarious actors. We also examine the implications of one stated purpose for the recreation of horsepox virus: the development of a smallpox vaccine. If the development is successful, it could take advantage of US government incentives for the priority FDA review of medical countermeasures (MCMs) against biosecurity threats. However, if this case leads to the determination that this incentive is counterproductive for security, the newly created priority review voucher program should be more clearly defined or limited based on need. Limiting the program could have costs that require further consideration, however, as general incentives for biodefense medical countermeasure development are required for MCMs to be available. Finally, while the recreation of horsepox virus was not technically trivial, nor was it cell-free, this experiment was a de facto demonstration of already-assumed scientific capabilities. The ability to recreate horsepox, or smallpox, will remain no matter what policy controls are put into place. It will be impossible to close off all avenues for nefarious misuse of gene synthesis, or misuse of biological materials more broadly. As a result, we advocate for the implementation of policy, regulations, and guidance that will make illicit recreation harder, more burdensome, more detectable, and, thus, more preventable without having sweeping negative consequences for the research enterprise. As part of our biosecurity efforts, we must also encourage and enable scientists to participate actively and to do all they can to safeguard their technical fields from irresponsible or illicit actions.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29091742     DOI: 10.1089/hs.2017.0081

Source DB:  PubMed          Journal:  Health Secur        ISSN: 2326-5094


  7 in total

1.  Efficient assembly of a large fragment of monkeypox virus genome as a qPCR template using dual-selection based transformation-associated recombination.

Authors:  Lei Yang; Lingqian Tian; Leshan Li; Qiuhong Liu; Xiang Guo; Yuan Zhou; Rongjuan Pei; Xinwen Chen; Yun Wang
Journal:  Virol Sin       Date:  2022-02-28       Impact factor: 6.947

2.  A Critical Analysis of the Scientific and Commercial Rationales for the De Novo Synthesis of Horsepox Virus.

Authors:  Gregory D Koblentz
Journal:  mSphere       Date:  2018-03-07       Impact factor: 4.389

3.  A Holistic Assessment of the Risks and Benefits of the Synthesis of Horsepox Virus.

Authors:  Diane DiEuliis; Gigi Kwik Gronvall
Journal:  mSphere       Date:  2018-03-07       Impact factor: 4.389

4.  The Need for Modernization of Biosecurity in the Post-COVID World.

Authors:  Diane DiEuliis; James Giordano
Journal:  mSphere       Date:  2022-02-28       Impact factor: 5.029

5.  Inoculating science against potential pandemics and information hazards.

Authors:  Kevin M Esvelt
Journal:  PLoS Pathog       Date:  2018-10-04       Impact factor: 6.823

6.  Synthetic horsepox viruses and the continuing debate about dual use research.

Authors:  Ryan S Noyce; David H Evans
Journal:  PLoS Pathog       Date:  2018-10-04       Impact factor: 6.823

7.  Adamantane derivatives as potential inhibitors of p37 major envelope protein and poxvirus reproduction. Design, synthesis and antiviral activity.

Authors:  Vadim A Shiryaev; Michael Yu Skomorohov; Marina V Leonova; Nikolai I Bormotov; Olga A Serova; Larisa N Shishkina; Alexander P Agafonov; Rinat A Maksyutov; Yuri N Klimochkin
Journal:  Eur J Med Chem       Date:  2021-04-29       Impact factor: 7.088

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.